Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1.

    The emerging role of cannabinoid neuromodulators in symptom management.

    Source

    The Harry R. Horvitz Center for Palliative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA. davism6@ccf.org

    Abstract

    INTRODUCTION:

    The cannabinoids nabilone (Cesamet) and dronabinol (Marinol) are indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in cancer patients who have failed to respond adequately to conventional antiemetic therapy.

    DISCUSSION:

    The endocannabinoid (CB) system interacts with numerous other systems and pharmaceutical cannabinoids target ubiquitous CB1 and CB2 receptors in the central nervous system and periphery, relieving nausea and vomiting and pain.

    SUMMARY:

    The benefits of this novel class of medications in cancer may extend beyond CINV, as indicated by data from preclinical studies and animal models.

    PMID:
    17139494
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk